Stocks›Healthcare›SLXN

SLXN

SILEXION THERAPEUTICS CORP
NasdaqResearch view
$0.260+1.28%
Sep 25 close · 1D EOD · Databento
HealthcareBiological Products, (No Diagnostic Substances)Micro-capSEC EDGAR FY 2025-12-31

The numbers · FY2025, filed

SEC EDGAR
Market cap$1M
Revenue$155,000+453.60%
Net income$-11.9M
EPS, diluted$89.61−97.70%
Operating margin-7504.5%
Return on equity-457.6%
All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31
SectorHealthcare
Market Cap$1.4M
Enterprise Value$-4.6M
Income$-11.9M
Sales$155,000
Book/sh$0.47
Cash/sh$1.09
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio—
Current Ratio2.41
Debt/Eq—
EPS (ttm)$89.61
EPS this Y-97.7%
EPS past 3/5Y—
Sales past 3/5Y—
EPS Y/Y TTM-97.7%
Sales Y/Y TTM453.6%
Shs Outstand5.56M
ROA-165.1%
ROE-457.6%
ROIC—
Gross Margin—
Oper. Margin-7504.5%
Profit Margin-7685.2%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$153,000
FY23
$28,000
FY24
$155,000
FY25

Operating leverage — margins

GrossOperatingNet
0%40%80%-7505%-7685%FY23FY24FY25
Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 3 FY · tap a row to explain it
USDFY2023FY2024FY2025

Same industry

In the screener →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.